Welcome to our dedicated page for Satellos Bioscience news (Ticker: $MSCLF), a resource for investors and traders seeking the latest updates and insights on Satellos Bioscience stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Satellos Bioscience's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Satellos Bioscience's position in the market.
Satellos Bioscience, a biotech company developing small molecule therapeutics for muscle diseases, announced the results of its Annual and Special Meeting of Shareholders held on May 14, 2024. All nominees listed in the Circular dated April 10, 2024, were elected as directors with over 99% of votes cast. Shareholders approved a potential reverse stock split in the range of 1-for-5 to 1-for-20, re-appointment of MNP LLP as auditors, a new Equity Incentive Plan, an advanced notice bylaw, and amendments to existing bylaws. 54.43% of common shares were represented at the meeting. The detailed voting results are available on Sedar+.
Satellos Bioscience announced its Q1 2024 financial and operational results.
Key highlights include preclinical advancements and GMP manufacturing for SAT-3247, with Phase 1 clinical trials on track to start mid-2024.
The company reported a cash balance of $33.2 million as of March 31, 2024, down from $39.6 million at the end of 2023.
Net loss for Q1 2024 was $6.9 million, significantly higher than the $1.7 million loss in Q1 2023, due to increased R&D and G&A expenses.
Satellos also received Orphan Drug status from the FDA for SAT-3247 and plans to present at the PPMD conference in June 2024.